# REGEN BIOPHARMA, INC. (RGBP) · Edgar & Edgarette company card

> Regen Biopharma (RGBP) grew revenue 0.0% in FY2025 to $0 million, operating margin -143% against a -3.8% median for pharmaceutical preparations, equity -2287% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1589150 · fiscal year ended 2025-09-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/RGBP) · [JSON](https://www.pops4.com/boards/company/RGBP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $236,561 |
| Revenue growth, 1 year | 0.0% |
| Revenue growth per year | 40.2% |
| Operating margin | -143.1% (prior year -176.4%) |
| Net margin | -538.8% |
| Operating cash flow | −$383,591 |
| Capital spending | — |
| Free cash flow | — |
| Cash | $69,555 |
| Long-term debt | — |
| Total assets | $274,628 |
| Total equity | −$6M |
| Equity ÷ assets | -2287.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -416.82 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late quarterly report notice, auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$384K in FY2025); operating loss: a margin of -143.1% in FY2025; revenue is hard to predict: its 80% range is ±68%

## Edgarette's reading

Exposure: revenue $237K (FY2025). Experience: revenue up 0.0% on the year, up 40.2% a year over 4 years; operating margin -143.1%, up from -176.4%. Soundness: equity -2287.2% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $114K and $596K next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $102K to $670K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -143.1% against a -3.8% median; growth 0.0% against 13.7%.

Range logged 2026-11-03, receipt 624cdabbefeeec9b, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-Q Late quarterly report notice: 1, latest 2026-08-13 ([filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226037682/0001493152-26-037682-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-07-15 ([filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/0001493152-26-033364-index.htm))

## Recent filings

- 8-K · filed 2026-11-02 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226049508/0001493152-26-049508-index.htm)
- 10-Q · filed 2026-08-17 · [filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226038576/0001493152-26-038576-index.htm)
- 8-K · filed 2026-07-15 · 1.01 Entry into a Material Definitive Agreement; 4.01 Changes in Registrant's Certifying Accountant; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/0001493152-26-033364-index.htm)
- 10-Q · filed 2026-05-14 · [filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226022924/0001493152-26-022924-index.htm)
- 8-K · filed 2026-03-04 · 3.02 Unregistered Sales of Equity Securities · [filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226008837/0001493152-26-008837-index.htm)
- 10-Q · filed 2026-02-13 · [filing](https://www.sec.gov/Archives/edgar/data/1589150/000149315226006526/0001493152-26-006526-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001589150.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1589150

## Cite

POPS4, Edgar & Edgarette: REGEN BIOPHARMA, INC. (RGBP) company card, from the company's own SEC filings, accessed 2026-11-03, https://www.pops4.com/boards/company/RGBP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.